CytomX Therapeutics (CTMX) Competitors $0.63 0.00 (-0.29%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CTMX vs. TNGX, TARA, ACTU, LYEL, GLSI, IKT, PRQR, FDMT, NMRA, and LRMRShould you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include Tango Therapeutics (TNGX), Protara Therapeutics (TARA), Actuate Therapeutics (ACTU), Lyell Immunopharma (LYEL), Greenwich LifeSciences (GLSI), Inhibikase Therapeutics (IKT), ProQR Therapeutics (PRQR), 4D Molecular Therapeutics (FDMT), Neumora Therapeutics (NMRA), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry. CytomX Therapeutics vs. Tango Therapeutics Protara Therapeutics Actuate Therapeutics Lyell Immunopharma Greenwich LifeSciences Inhibikase Therapeutics ProQR Therapeutics 4D Molecular Therapeutics Neumora Therapeutics Larimar Therapeutics Tango Therapeutics (NASDAQ:TNGX) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their community ranking, dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation. Does the media prefer TNGX or CTMX? In the previous week, Tango Therapeutics had 4 more articles in the media than CytomX Therapeutics. MarketBeat recorded 9 mentions for Tango Therapeutics and 5 mentions for CytomX Therapeutics. Tango Therapeutics' average media sentiment score of 0.77 beat CytomX Therapeutics' score of 0.54 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is TNGX or CTMX more profitable? CytomX Therapeutics has a net margin of 10.96% compared to Tango Therapeutics' net margin of -284.42%. CytomX Therapeutics' return on equity of -41.47% beat Tango Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tango Therapeutics-284.42% -49.64% -32.00% CytomX Therapeutics 10.96%-41.47%8.11% Do analysts prefer TNGX or CTMX? Tango Therapeutics currently has a consensus price target of $12.33, indicating a potential upside of 852.38%. CytomX Therapeutics has a consensus price target of $4.77, indicating a potential upside of 666.54%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Tango Therapeutics is more favorable than CytomX Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tango Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00CytomX Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has preferable valuation and earnings, TNGX or CTMX? CytomX Therapeutics has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTango Therapeutics$42.07M3.33-$101.74M-$1.21-1.07CytomX Therapeutics$138.10M0.36-$570K$0.381.64 Which has more volatility & risk, TNGX or CTMX? Tango Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Does the MarketBeat Community believe in TNGX or CTMX? CytomX Therapeutics received 346 more outperform votes than Tango Therapeutics when rated by MarketBeat users. However, 74.36% of users gave Tango Therapeutics an outperform vote while only 65.22% of users gave CytomX Therapeutics an outperform vote. CompanyUnderperformOutperformTango TherapeuticsOutperform Votes2974.36% Underperform Votes1025.64% CytomX TherapeuticsOutperform Votes37565.22% Underperform Votes20034.78% Do institutionals & insiders hold more shares of TNGX or CTMX? 79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 6.3% of Tango Therapeutics shares are owned by company insiders. Comparatively, 7.0% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryCytomX Therapeutics beats Tango Therapeutics on 10 of the 18 factors compared between the two stocks. Remove Ads Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTMX vs. The Competition Export to ExcelMetricCytomX TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.87M$6.28B$5.30B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E Ratio3.666.7321.6917.67Price / Sales0.36221.51371.5292.57Price / CashN/A65.6738.1534.64Price / Book-0.885.776.373.94Net Income-$570,000.00$142.23M$3.20B$247.37M7 Day Performance24.45%3.19%1.91%0.64%1 Month Performance-4.16%-13.67%-9.32%-6.98%1 Year Performance-66.53%-12.37%9.64%-0.32% CytomX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTMXCytomX Therapeutics4.039 of 5 stars$0.63-0.3%$4.77+657.9%-67.9%$50.44M$138.10M3.70170Analyst ForecastNews CoverageTNGXTango Therapeutics1.9276 of 5 stars$1.27flat$12.33+871.1%-81.2%$137.30M$42.07M-1.0890Analyst ForecastAnalyst RevisionNews CoveragePositive NewsGap DownTARAProtara Therapeutics1.9893 of 5 stars$3.70-5.1%$22.50+508.1%+46.8%$136.04MN/A-1.3130Analyst ForecastNews CoverageACTUActuate TherapeuticsN/A$6.82-1.0%$20.00+193.3%N/A$133.21MN/A0.0010Gap UpLYELLyell Immunopharma3.2279 of 5 stars$0.45-3.9%$1.00+123.9%-80.9%$131.85M$61,000.00-0.57270Analyst ForecastNews CoveragePositive NewsGap DownGLSIGreenwich LifeSciences1.9679 of 5 stars$9.59+8.6%$38.00+296.2%-37.2%$126.06MN/A-11.993Earnings ReportUpcoming EarningsNews CoverageGap DownHigh Trading VolumeIKTInhibikase Therapeutics1.4368 of 5 stars$1.68-8.7%$6.50+286.9%-13.4%$124.90M$260,000.00-0.636Gap DownPRQRProQR Therapeutics2.1627 of 5 stars$1.17-0.8%$9.50+712.0%-41.8%$123.10M$18.91M-3.66180Short Interest ↓News CoverageFDMT4D Molecular Therapeutics2.5702 of 5 stars$2.65-4.3%$26.71+908.1%-88.2%$122.70M$37,000.00-0.93120Positive NewsNMRANeumora Therapeutics3.1624 of 5 stars$0.75+2.3%$9.29+1,132.8%-94.1%$122.00MN/A-0.40108LRMRLarimar Therapeutics3.5511 of 5 stars$1.87-4.6%$19.63+949.5%-74.2%$119.73MN/A-1.6330Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies Tango Therapeutics Competitors Protara Therapeutics Competitors Actuate Therapeutics Competitors Lyell Immunopharma Competitors Greenwich LifeSciences Competitors Inhibikase Therapeutics Competitors ProQR Therapeutics Competitors 4D Molecular Therapeutics Competitors Neumora Therapeutics Competitors Larimar Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTMX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTMX Stock Free CTMX Stock Alerts